Physician profile
Vignesh Packiam
NPI 1366707242
$111,552.59
in general payments reported to CMS, 2019-2025
13 companies · $72K in 2025
The $72K reported for 2025 was more than what 99% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2021: $315 · 2022: $455 · 2023: $609 · 2024: $37K · 2025: $72K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48K · Honoraria: $36K · Consulting Fee: $15K · Travel and Lodging: $7,672 · Food and Beverage: $4,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $47,777.23 |
| Honoraria | $35,624.00 |
| Consulting Fee | $15,227.00 |
| Travel and Lodging | $7,671.54 |
| Food and Beverage | $4,156.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $42,177.57 | 2022-2025 | Jelmyto |
| Ferring Pharmaceuticals INC. | $24,578.32 | 2024-2025 | Adstiladrin |
| Janssen Biotech, INC. | $19,655.75 | 2024-2025 | Rybrevant, Carvykti, Erleada |
| Photocure INC | $18,189.02 | 2021-2025 | Cysview |
| Pfizer INC. | $3,840.00 | 2025 | |
| Karl Storz Endoscopy-America | $1,351.97 | 2024-2025 | Hopkins |
| Koelis INC. | $482.13 | 2023-2024 | |
| Edap Technomed INC | $373.63 | 2024-2025 | |
| Olympus Corporation of The Americas | $325.73 | 2019 | |
| Seagen INC. | $254.44 | 2021-2022 | |
| Immunitybio, INC. | $136.37 | 2024 | |
| Exelixis INC. | $125.00 | 2022 | |
| Myovant Sciences INC. | $62.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vignesh Packiam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.